Cassava Sciences Good News and an Unwarranted Sell-Off. A New Drug Approval for Bristol-Myers Squibb and ImmunoGen Quarterly Results

Cassava Sciences Inc
Following Cassava Sciences Inc successful and promising presentations, all the titles of the news and articles written by fair professionals have been as follows: “Cassava Sciences announces positive biomarkers’ data and positive Cognition Data following the treatment with Simufilam”

These titles never moved from the Internet even after a huge sell-off occurred. 

Indeed, the improvement in cognition demonstrated by the data was the first to happen in the history of treating Alzheimer's disease and other kinds of dementia. When it comes to the improvements shown by biomarkers’ data they were significant in Alzheimer’s disease . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.